The surge is fueled by a rapidly expanding gene and cell therapy pipeline, with over 4,000 therapies in development and more ...

For the past few years, I have had to ask myself a question I never asked before in my life: What should we call the era we’re living in today? I was born into the “Cold War” era, and most of my ...

ROCKVILLE, Md., Oct. 8, 2025 /PRNewswire/ -- Ascend Advanced Therapies (Ascend), a gene-to-GMP development partner, today announced that its European patent EP3722434, protecting EpyQ®, the company's ...

Under a strategic collaboration between Wacker and Gearbox Biosciences, both the companies will work together to accelerate the development of next-generation plasmid DNA (a critical raw material for ...

Wacker Chemie AG (Munich, Germany)’s has combined expertise in GMP manufacturing of biologics, including pDNA, with Gearbox Bioscience’s innovative solutions for antibiotic-free plasmid proliferation ...

Last week, WACKER Chemie AG announced its collaboration with Gearbox Biosciences to produce plasmid DNA (pDNA), a key starting ingredient for mRNA vaccines and cell and gene therapies (CGTs). The ...

IMUNON announces promising Phase 1 results for IMNN-101, a DNA plasmid vaccine demonstrating enhanced durability and potential advantages over mRNA vaccines. Phase 1 clinical trial results of IMNN-101 ...